ZA966364B - Antineoplastic agents - Google Patents

Antineoplastic agents

Info

Publication number
ZA966364B
ZA966364B ZA966364A ZA966364A ZA966364B ZA 966364 B ZA966364 B ZA 966364B ZA 966364 A ZA966364 A ZA 966364A ZA 966364 A ZA966364 A ZA 966364A ZA 966364 B ZA966364 B ZA 966364B
Authority
ZA
South Africa
Prior art keywords
pct
sec
antineoplastic agents
date
preventing
Prior art date
Application number
ZA966364A
Other languages
English (en)
Inventor
Eric Niesor
Craig Leigh Bentzen
Lan Mong Nguyen
Jean-Lu Thuillard
Hieu Trung Phan
Jean Flach
Original Assignee
Symphar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphar Sa filed Critical Symphar Sa
Publication of ZA966364B publication Critical patent/ZA966364B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/404—Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
ZA966364A 1995-07-28 1996-07-26 Antineoplastic agents ZA966364B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH02213/95A CH690163A5 (fr) 1995-07-28 1995-07-28 Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.

Publications (1)

Publication Number Publication Date
ZA966364B true ZA966364B (en) 1997-02-11

Family

ID=4228513

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA966364A ZA966364B (en) 1995-07-28 1996-07-26 Antineoplastic agents

Country Status (15)

Country Link
US (1) US6127350A (de)
EP (1) EP0845991B1 (de)
JP (1) JPH11511127A (de)
CN (1) CN1091601C (de)
AT (1) ATE212847T1 (de)
AU (1) AU723094B2 (de)
CA (1) CA2228212A1 (de)
CH (1) CH690163A5 (de)
DE (1) DE69619117T2 (de)
DK (1) DK0845991T3 (de)
ES (1) ES2172675T3 (de)
HK (1) HK1015686A1 (de)
PT (1) PT845991E (de)
WO (1) WO1997004785A1 (de)
ZA (1) ZA966364B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603637D0 (en) * 1996-02-21 1996-04-17 Smithkline Beecham Plc Process
WO1999033473A1 (fr) * 1997-12-25 1999-07-08 Toray Industries, Inc. Remedes contre les maladies intramedullaires
ATE385797T1 (de) * 1999-12-03 2008-03-15 Univ California At San Diego Phosphonatverbindungen
GB0019272D0 (en) * 2000-08-04 2000-09-27 Symphar Sa Pharmaceutical compounds
FR2827289B1 (fr) * 2001-07-16 2004-07-23 Univ Paris 13 Nouveau derive d'acide diphosphonique, son application en therapeutique et procede de preparation
CA2451881A1 (fr) 2001-07-16 2003-01-30 Universite Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
WO2003032909A2 (en) * 2001-10-18 2003-04-24 Ilex Products, Inc. Methods of treating skin with diphosphonate derivatives
EP1506208A4 (de) * 2002-05-11 2006-05-24 Ilex Products Inc 1,1- und 1,2-bisphosphonate als modulatoren von apolipoprotein e
JP2006503023A (ja) * 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
WO2004026243A2 (en) * 2002-09-19 2004-04-01 Ilex Oncology Research, Sarl Therapeutic uses of linear ketophosphonates
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RS58936B1 (sr) 2007-01-10 2019-08-30 Msd Italia Srl Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
EP2152700B1 (de) 2007-05-21 2013-12-11 Novartis AG Csf-1r-hemmer, zusammensetzungen und anwendungsverfahren
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
EP2519517B1 (de) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Typ-ii-raf-kinase-hemmer
KR20130006664A (ko) 2010-03-16 2013-01-17 다나-파버 캔서 인스티튜트 인크. 인다졸 화합물 및 그의 용도
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2013142875A1 (en) * 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014085216A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
EP3057956B1 (de) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclische inhibitoren der cyclin-dependent-kinase 7 (cdk7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3209671B8 (de) 2014-10-21 2019-07-31 Council of Scientific and Industrial Research Alkyliden-phosphonat-ester als p-glycoproteininduktoren
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106986789B (zh) * 2016-01-20 2019-07-16 中国人民解放军军事医学科学院生物医学分析中心 对苯二酚类化合物及其制备方法与在抗肿瘤或免疫调节中的应用
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (de) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5-inhibitoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675422A5 (de) * 1988-03-31 1990-09-28 Symphar Sa
JPH0377894A (ja) * 1989-08-18 1991-04-03 Toray Ind Inc メチレンジホスホン酸化合物

Also Published As

Publication number Publication date
DK0845991T3 (da) 2002-05-27
CH690163A5 (fr) 2000-05-31
WO1997004785A1 (en) 1997-02-13
CN1091601C (zh) 2002-10-02
DE69619117T2 (de) 2002-09-19
ATE212847T1 (de) 2002-02-15
AU6787496A (en) 1997-02-26
PT845991E (pt) 2002-07-31
CA2228212A1 (en) 1997-02-13
EP0845991B1 (de) 2002-02-06
JPH11511127A (ja) 1999-09-28
US6127350A (en) 2000-10-03
ES2172675T3 (es) 2002-10-01
DE69619117D1 (de) 2002-03-21
EP0845991A2 (de) 1998-06-10
HK1015686A1 (en) 1999-10-22
AU723094B2 (en) 2000-08-17
CN1192148A (zh) 1998-09-02

Similar Documents

Publication Publication Date Title
ZA966364B (en) Antineoplastic agents
AU6738696A (en) Halobenzimidazoles and their use as microbicides
GR3033827T3 (en) New compounds and their compositions having anti-inflammatory and anti-thrombotic activities
GR3035621T3 (en) New pyrimidone derivatives with antifungal activity
AU6613896A (en) Chemical compounds
ES2104386T3 (es) Compuesto intermedio para la acitromicina.
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
PL333429A1 (en) Benzonaphtyridines useful in particular in treating bronchial diseases
SE9401728D0 (sv) New compounds II
AU5648496A (en) Pyrazolo-(1,5a)pyrimidines, their preparation and their use
NZ300942A (en) 1-aryl-2-acylamino-ethane derivatives as neurokinin 1 antagonists
HU9700024D0 (en) Imidazopyridin-azolidinones
IL127321A0 (en) N-sulphonylimidazoles and the use thereof as microbicides
HRP950271B1 (en) New peptide active substance and the production thereof
PL323305A1 (en) Applications of allyl amines
ZA961044B (en) New pyridine and pyridazine derivatives, processes for the production thereof and pharmaceutical agents containing these compounds.
SE9404438D0 (sv) New process
HK1024872A1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
PL322847A1 (en) Condensed b-carbolins
MX9802933A (es) Derivados novedosos de amina de 2", 3"-didesoxiglicosidos de epipodofilotoxina, metodo de preparacion de los mismos y uso de los mismos con un farmaco y para tratamientos anticancer.